Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents

ACS Chemical Biology

Volumn 9, Issue 5, 2014, Pages 1204-1212

  Gilchrist, John ^a   Dutton, Stacey ^b   Diaz Bustamante, Marcelo ^a   McPherson, Annie ^b   Olivares, Nicolas ^a   Kalia, Jeet ^c   Escayg, Andrew ^b   Bosmans, Frank ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 (PHENYLMETHYL) 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE 5 METHYL; 1 [(3 FLUOROPHENYL)METHYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE 5 AMINE; 1 [(3 FLUOROPHENYL)METHYL] 1H 1,2,3 TRIAZOLE 4 HYDROXYMETHYL; 1 [(4 FLUOROPHENYL)METHYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE 5 AMINE; ANTICONVULSIVE AGENT; DIMETHYL SULFOXIDE; RUFINAMIDE; SODIUM CHANNEL NAV1.1; SODIUM CHANNEL NAV1.2; SODIUM CHANNEL NAV1.3; SODIUM CHANNEL NAV1.6; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPOLARIZATION; DRUG MECHANISM; ELECTRIC POTENTIAL; EMBRYO; HIPPOCAMPUS; MODULATION; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE THRESHOLD; STRUCTURE ACTIVITY RELATION; TONIC CLONIC SEIZURE; ANIMAL; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG DEVELOPMENT; DRUG EFFECTS; EPILEPSY; HUMAN; MALE; METABOLISM; SPRAGUE DAWLEY RAT; XENOPUS;

ACTION POTENTIALS; ANIMALS; ANTICONVULSANTS; CELLS, CULTURED; DRUG DISCOVERY; EPILEPSY; HIPPOCAMPUS; HUMANS; MALE; MICE; NAV1.1 VOLTAGE-GATED SODIUM CHANNEL; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES; XENOPUS;

EID: 84900873277     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb500108p     Document Type: Article

References (63)

1. Trevathan, E., Murphy, C. C., and Yeargin-Allsopp, M. (1997) Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children Epilepsia 38, 1283-1288
2. Arzimanoglou, A., French, J., Blume, W. T., Cross, J. H., Ernst, J. P., Feucht, M., Genton, P., Guerrini, R., Kluger, G., Pellock, J. M., Perucca, E., and Wheless, J. W. (2009) Lennox-Gastaut syndrome: A consensus approach on diagnosis, assessment, management, and trial methodology Lancet Neurol. 8, 82-93
3. Brodie, M. J., Rosenfeld, W. E., Vazquez, B., Sachdeo, R., Perdomo, C., Mann, A., and Arroyo, S. (2009) Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo-controlled trial Epilepsia 50, 1899-1909
4. Deeks, E. D. and Scott, L. J. (2006) Rufinamide CNS Drugs 20, 751-760, 761 (discussion)
5. White, H. S., Franklin, M. R., Kupferberg, H. J., Schmutz, M., Stables, J. P., and Wolf, H. H. (2008) The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models Epilepsia 49, 1213-1220
6. Coppola, G., Zamponi, N., Kluger, G., Mueller, A., Anna Rita, M., Parisi, P., Isone, C., Santoro, E., Curatolo, P., and Verrotti, A. (2012) Rufinamide for refractory focal seizures: An open-label, multicenter European study Seizure 22, 33-36
7. Critchley, D. J., Aluri, J., Boyd, P., Whayman, M., Narurkar, M., Delargy, H., and Bibbiani, F. (2011) Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: Results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjects Clin. Ther. 33, 146-157
8. May, T. W., Boor, R., Rambeck, B., Jurgens, U., Korn-Merker, E., and Brandt, C. (2011) Serum concentrations of rufinamide in children and adults with epilepsy: The influence of dose, age, and comedication Ther. Drug Monit. 33, 214-221
9. Catterall, W. A., Goldin, A. L., and Waxman, S. G. (2005) International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels Pharmacol. Rev. 57, 397-409
10. Escayg, A. and Goldin, A. L. (2010) Sodium channel SCN1A and epilepsy: Mutations and mechanisms Epilepsia 51, 1650-1658
11. Mantegazza, M., Curia, G., Biagini, G., Ragsdale, D. S., and Avoli, M. (2010) Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders Lancet Neurol. 9, 413-424
12. Ragsdale, D. S. (2008) How do mutant Nav1.1 sodium channels cause epilepsy? Brain Res. Rev. 58, 149-159
13. Oliva, M., Berkovic, S. F., and Petrou, S. (2012) Sodium channels and the neurobiology of epilepsy Epilepsia 53, 1849-1859
14. Catterall, W. A. (2014) Sodium channels, inherited epilepsy, and antiepileptic drugs Annu. Rev. Pharmacol. Toxicol. 54, 317-338
15. McLean, M. J., Schmutz, M., Pozza, M. F., and Wamil, A. W. (2005) Effects of rufinamide on sodium-dependent action potential firing and sodium currents of rodent central neurons Epilepsia 46, 375-375
16. Niespodziany, I., Leclere, N., Vandenplas, C., Foerch, P., and Wolff, C. (2013) Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation J. Neurosci. Res. 91, 436-443
17. Whitaker, W. R., Clare, J. J., Powell, A. J., Chen, Y. H., Faull, R. L., and Emson, P. C. (2000) Distribution of voltage-gated sodium channel -subunit and -subunit mRNAs in human hippocampal formation, cortex, and cerebellum J. Comp. Neurol. 422, 123-139
18. Catterall, W. A., Kalume, F., and Oakley, J. C. (2010) NaV1.1 channels and epilepsy J. Physiol. 588, 1849-1859
19. Escayg, A., MacDonald, B. T., Meisler, M. H., Baulac, S., Huberfeld, G., An-Gourfinkel, I., Brice, A., LeGuern, E., Moulard, B., Chaigne, D., Buresi, C., and Malafosse, A. (2000) Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2 Nat. Genet. 24, 343-345
20. Papale, L. A., Beyer, B., Jones, J. M., Sharkey, L. M., Tufik, S., Epstein, M., Letts, V. A., Meisler, M. H., Frankel, W. N., and Escayg, A. (2009) Heterozygous mutations of the voltage-gated sodium channel SCN8A are associated with spike-wave discharges and absence epilepsy in mice Hum. Mol. Genet. 18, 1633-1641
21. Veeramah, K. R., O'Brien, J. E., Meisler, M. H., Cheng, X., Dib-Hajj, S. D., Waxman, S. G., Talwar, D., Girirajan, S., Eichler, E. E., Restifo, L. L., Erickson, R. P., and Hammer, M. F. (2012) De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP Am. J. Hum. Genet. 90, 502-510
22. Hains, B. C. and Waxman, S. G. (2007) Sodium channel expression and the molecular pathophysiology of pain after SCI Prog. Brain Res. 161, 195-203
23. Estacion, M., Gasser, A., Dib-Hajj, S. D., and Waxman, S. G. (2010) A sodium channel mutation linked to epilepsy increases ramp and persistent current of Nav1.3 and induces hyperexcitability in hippocampal neurons Exp. Neurol. 224, 362-368
24. Vanoye, C. G., Gurnett, C. A., Holland, K. D., George, A. L., Jr., and Kearney, J. A. (2014) Novel SCN3A variants associated with focal epilepsy in children Neurobiol. Dis. 62, 313-322
25. O'Kelly, I., Butler, M. H., Zilberberg, N., and Goldstein, S. A. (2002) Forward transport. 14-3-3 binding overcomes retention in endoplasmic reticulum by dibasic signals Cell 111, 577-588
26. Boileau, A. J., Kucken, A. M., Evers, A. R., and Czajkowski, C. (1998) Molecular dissection of benzodiazepine binding and allosteric coupling using chimeric -aminobutyric acidA receptor subunits Mol. Pharmacol. 53, 295-303
27. Trudeau, M. C., Warmke, J. W., Ganetzky, B., and Robertson, G. A. (1995) HERG, a human inward rectifier in the voltage-gated potassium channel family Science 269, 92-95
28. Dutton, S. B., Makinson, C. D., Papale, L. A., Shankar, A., Balakrishnan, B., Nakazawa, K., and Escayg, A. (2012) Preferential inactivation of Scn1a in parvalbumin interneurons increases seizure susceptibility Neurobiol. Dis. 49C, 211-220
29. Burbidge, S. A., Dale, T. J., Powell, A. J., Whitaker, W. R., Xie, X. M., Romanos, M. A., and Clare, J. J. (2002) Molecular cloning, distribution and functional analysis of the NA(V)1.6. Voltage-gated sodium channel from human brain Brain Research. Molecular Brain Research 103, 80-90
30. Chen, Y. H., Dale, T. J., Romanos, M. A., Whitaker, W. R., Xie, X. M., and Clare, J. J. (2000) Cloning, distribution and functional analysis of the type III sodium channel from human brain Eur. J. Neurosci. 12, 4281-4289
31. Mantegazza, M., Yu, F. H., Powell, A. J., Clare, J. J., Catterall, W. A., and Scheuer, T. (2005) Molecular determinants for modulation of persistent sodium current by G-protein betagamma subunits J. Neurosci. 25, 3341-3349
32. + channel expressed in a stable mammalian cell line Pfluegers Arch. 441, 425-433
33. Suter, M. R., Kirschmann, G., Laedermann, C. J., Abriel, H., and Decosterd, I. (2013) Rufinamide Attenuates Mechanical Allodynia in a Model of Neuropathic Pain in the Mouse and Stabilizes Voltage-gated Sodium Channel Inactivated State Anesthesiology 118, 160-172
34. Ledwell, J. L. and Aldrich, R. W. (1999) Mutations in the S4 region isolate the final voltage-dependent cooperative step in potassium channel activation J. Gen. Physiol. 113, 389-414
35. Kwan, P., Sills, G. J., and Brodie, M. J. (2001) The mechanisms of action of commonly used antiepileptic drugs Pharmacol. Ther. 90, 21-34
36. Lipkind, G. M. and Fozzard, H. A. (2010) Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore Mol. Pharmacol. 78, 631-638
37. Rogawski, M. A. (2006) Diverse mechanisms of antiepileptic drugs in the development pipeline Epilepsy Res. 69, 273-294
38. + current of mammalian CNS neurones NeuroReport 6, 1778-1780
39. Arroyo, S. (2007) Rufinamide Neurotherapeutics 4, 155-162
40. Mohler, H. (2006) GABA(A) receptor diversity and pharmacology Cell Tissue Res. 326, 505-516
41. Trimmer, J. S. and Rhodes, K. J. (2004) Localization of voltage-gated ion channels in mammalian brain Annu. Rev. Physiol. 66, 477-519
42. Sievers, F., Wilm, A., Dineen, D., Gibson, T. J., Karplus, K., Li, W., Lopez, R., McWilliam, H., Remmert, M., Soding, J., Thompson, J. D., and Higgins, D. G. (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega Mol. Syst. Biol. 7, 539
43. Applegate, C. D., Samoriski, G. M., and Ozduman, K. (1997) Effects of valproate, phenytoin, and MK-801 in a novel model of epileptogenesis Epilepsia 38, 631-636
44. Barton, M. E., Klein, B. D., Wolf, H. H., and White, H. S. (2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy Epilepsy Res. 47, 217-227
45. Ahmad, S., Dahllund, L., Eriksson, A. B., Hellgren, D., Karlsson, U., Lund, P. E., Meijer, I. A., Meury, L., Mills, T., Moody, A., Morinville, A., Morten, J., ODonnell, D., Raynoschek, C., Salter, H., Rouleau, G. A., and Krupp, J. J. (2007) A stop codon mutation in SCN9A causes lack of pain sensation Hum. Mol. Genet. 16, 2114-2121
46. Singh, N. A., Pappas, C., Dahle, E. J., Claes, L. R., Pruess, T. H., De Jonghe, P., Thompson, J., Dixon, M., Gurnett, C., Peiffer, A., White, H. S., Filloux, F., and Leppert, M. F. (2009) A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome PLoS Genet. 5, e1000649
47. Glauser, T., Kluger, G., Sachdeo, R., Krauss, G., Perdomo, C., and Arroyo, S. (2008) Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome Neurology 70, 1950-1958
48. Hancock, E. C. and Cross, H. H. (2009) Treatment of Lennox-Gastaut syndrome Cochrane Database of Systematic Reviews CD003277
49. Selmer, K. K., Lund, C., Brandal, K., Undlien, D. E., and Brodtkorb, E. (2009) SCN1A mutation screening in adult patients with Lennox-Gastaut syndrome features Epilepsy & Behavior 16, 555-557
50. Claes, L. R., Deprez, L., Suls, A., Baets, J., Smets, K., Van Dyck, T., Deconinck, T., Jordanova, A., and De Jonghe, P. (2009) The SCN1A variant database: A novel research and diagnostic tool Hum. Mutat. 30, E904-E920
51. Spampanato, J., Kearney, J. A., de Haan, G., McEwen, D. P., Escayg, A., Aradi, I., MacDonald, B. T., Levin, S. I., Soltesz, I., Benna, P., Montalenti, E., Isom, L. L., Goldin, A. L., and Meisler, M. H. (2004) A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for subunit interaction J. Neurosci. 24, 10022-10034
52. Volkers, L., Kahlig, K. M., Verbeek, N. E., Das, J. H., van Kempen, M. J., Stroink, H., Augustijn, P., van Nieuwenhuizen, O., Lindhout, D., George, A. L., Jr., Koeleman, B. P., and Rook, M. B. (2011) Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus or Dravet syndrome Eur. J. Neurosci. 34, 1268-1275
53. Lossin, C. (2009) A catalog of SCN1A variants Brain Dev. 31, 114-130
54. Dichgans, M., Freilinger, T., Eckstein, G., Babini, E., Lorenz-Depiereux, B., Biskup, S., Ferrari, M. D., Herzog, J., van den Maagdenberg, A. M., Pusch, M., and Strom, T. M. (2005) Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine Lancet 366, 371-377
55. Cestele, S., Labate, A., Rusconi, R., Tarantino, P., Mumoli, L., Franceschetti, S., Annesi, G., Mantegazza, M., and Gambardella, A. (2013) Divergent effects of the T1174S SCN1A mutation associated with seizures and hemiplegic migraine Epilepsia 54, 927-935
56. Moran, M. and Woiwode, T. (2009) Rufinamide for the Treatment of Post-Traumatic Stress Disorder. U.S. Patent 20090054414 A1.
57. Oakley, J. C., Kalume, F., Yu, F. H., Scheuer, T., and Catterall, W. A. (2009) Temperature-and age-dependent seizures in a mouse model of severe myoclonic epilepsy in infancy Proc. Natl. Acad. Sci. U.S.A. 106, 3994-3999
58. Yu, F. H., Mantegazza, M., Westenbroek, R. E., Robbins, C. A., Kalume, F., Burton, K. A., Spain, W. J., McKnight, G. S., Scheuer, T., and Catterall, W. A. (2006) Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy Nat. Neurosci. 9, 1142-1149
59. Han, S., Tai, C., Westenbroek, R. E., Yu, F. H., Cheah, C. S., Potter, G. B., Rubenstein, J. L., Scheuer, T., de la Iglesia, H. O., and Catterall, W. A. (2012) Autistic-like behaviour in Scn1a± mice and rescue by enhanced GABA-mediated neurotransmission Nature 489, 385-390
60. Weiss, L. A., Escayg, A., Kearney, J. A., Trudeau, M., MacDonald, B. T., Mori, M., Reichert, J., Buxbaum, J. D., and Meisler, M. H. (2003) Sodium channels SCN1A, SCN2A and SCN3A in familial autism Mol. Psychiatry 8, 186-194
61. Rogawski, M. A. and Loscher, W. (2004) The neurobiology of antiepileptic drugs Nat. Rev. Neurosci. 5, 553-564
62. Rowley, N. M. and White, H. S. (2010) Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: Correlation with other seizure and epilepsy models Epilepsy Res. 92, 163-169
63. Stohr, T., Kupferberg, H. J., Stables, J. P., Choi, D., Harris, R. H., Kohn, H., Walton, N., and White, H. S. (2007) Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy Epilepsy Res. 74, 147-154